Abstract
In addition to genetically variable metabolic enzymes such as Cyp p450 proteins, blood and tissue levels of many drugs are influenced by controlled transport across compartmental boundaries. Major determinants in these transport processes are ATP-dependent efflux pumps such as P-glycoprotein and related proteins (eg MRPs), which can influence the bioavailability and CNS concentrations, as well as disposition of drugs. In addition to its recognized role in the development of multiple chemotherapy resistances, experimental evidence for the relevant influence of the MDR1 gene encoded P-glycoprotein, on the pharmacology of many other drugs has been gathered by the analyses of knockout mice, as well as in clinical studies. Recently, functional genetic polymorphisms in the MDR1 gene have been identified which influence the distribution and bioavailability of PGP substrates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Juliano RL, Ling V . A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim Biophys Acta 1976 455: 152–162
Cole SP, Bhardwaj G, Gerlach JH et al . Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 1992 258: 1650–1654
Borst P, Evers R, Kool M, Wijnholds J . The multidrug resistance protein family Biochim Biophys Acta 1999 1461: 347–357
Keppler D, Leier I, Jedlitschky G . Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2 Biol Chem 1997 378: 787–791
Cui Y, Konig J, Gerlach JH et al . Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells Mol Pharmacol 1999 55: 929–937
Cole SP, Deeley RG . Multidrug resistance mediated by ATP-binding cassette transporter protein MRP Bioassays 1998 20: 931–949
Chen CJ, Chin JE, Gerlach JH et al . Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells Cell 1986 47: 381–389
Gottesman MM, Pastan I, Ambudkar SV . P-glycoprotein and multidrug resistance Curr Opin Genet Dev 1996 6: 610–617
Loe DW, Deeley RG, Cole SP . Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione Cancer Res 1998 58: 5130–5136
Loo TW, Clarke DM . Drug-stimulated ATPase activity of human P-glycoprotein is blocked by disulfide cross-linking between the nucleotide-binding sites J Biol Chem 2000 275: 19435–19438
Ramachandra M, Ambudkar SV, Gerlach JH et al . Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state Biochemistry 1998 37: 5010–5019
Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV . Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein Proc Natl Acad Sci USA 1997 94: 10594–10599
Gros P, Ben Neriah YB, Croop JM, Housman DE . Isolation and expression of a complementary DNA that confers multidrug resistance Nature 1986 323: 728–731
Ueda K, Cardarelli C, Gottesman MM, Pastan I . Expression of a full-length cDNA for the human ‘MDR1’ gene confers resistance to colchicine, doxorubicin, and vinblastine Proc Natl Acad Sci USA 1987 84: 3004–3008
Seelig A . A general pattern for substrate recognition by P-glycoprotein Eur J Biochem 1998 251: 252–261
Baekelandt MM, Holm R, Nesland JM, Trope CG, Kristensen GB . P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer Anticancer Res 2000 20: 1061–1067
Warnakulasuriya S, Jia C, Johnson N, Houghton J . p53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy J Pathol 2000 191: 33–38
van den Heuvel-Eibrink MM, Sonneveld P, Pieters R . The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia Int J Clin Pharmacol Ther 2000 38: 94–110
Ng IO, Liu CL, Fan ST, Ng M . Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response Am J Clin Pathol 2000 113: 355–363
Arts HJ, Katsaros D, de Gerlach JH et al . Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma Clin Cancer Res 1999 5: 2798–2805
Dhooge C, De Moerloose B, Gerlach JH et al . P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study Br J Haematol 1999 105: 676–683
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y . Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil Cancer Res 1981 41: 1967–1972
Ferry DR, Traunecker H, Kerr DJ . Clinical trials of P-glycoprotein reversal in solid tumours Eur J Cancer 1996 32A: 1070–1081
Okamura N, Hirai M, Gerlach JH et al . Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney J Pharmacol Exp Ther 1993 266: 1614–1619
Tamai I, Safa AR . Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding toP-glycoprotein in multidrug resistant cells J Biol Chem 1991 266: 16796–16800
Garrigos M, Mir LM, Orlowski S . Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase—further experimental evidence for a multisite model Eur J Biochem 1997 244: 664–673
Fromm MF . P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs Int J Clin Pharmacol Ther 2000 38: 69–74
Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Gerlach JH et al . The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin J Clin Invest 1999 104: 147–153
Thiebaut F, Tsuruo T, Gerlach JH et al . Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci USA 1987 84: 7735–7738
Ueda K, Clark DP, Gerlach JH et al . The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation J Biol Chem 1987 262: 505–508
Cordon-Cardo C, O’Brien JP, Gerlach JH et al . Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues J Histochem Cytochem 1990 38: 1277–1287
Thiebaut F, Tsuruo T, Gerlach JH et al . Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein J Histochem Cytochem 1989 37: 159–164
Rao VV, Dahlheimer JL, Gerlach JH et al . Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier Proc Natl Acad Sci USA 1999 96: 3900–3905
Borst P, Evers R, Kool M, Wijnholds J . The multidrug resistance protein family Biochim Biophys Acta 1999 1461: 347–357
Schinkel AH, Mayer U, Gerlach JH et al . Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins Proc Natl Acad Sci USA 1997 94: 4028–4033
Schinkel AH, Mol CA, Gerlach JH et al . Multidrug resistance and the role of P-glycoprotein knockout mice Eur J Cancer 1995 31A: 1295–1298
Smit JW, Schinkel AH, Weert B, Meijer DK . Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted Br J Pharmacol 1998 124: 416–424
Smit JW, Schinkel AH, Muller M, Weert B, Meijer DK . Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption Hepatology 1998 27: 1056–1063
Schinkel AH, Smit JJ, van Gerlach JH et al . Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 1994 77: 491–502
Mayer U, Wagenaar E, Gerlach JH et al . Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein Br J Pharmacol 1996 119: 1038–1044
Sparreboom A, van Asperen J, Gerlach JH et al . Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proc Natl Acad Sci USA 1997 94: 2031–2035
van Asperen J, Schinkel AH, Gerlach JH et al . Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein- deficient mice J Natl Cancer Inst 1996 88: 994–999
Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P . Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A J Clin Invest 1995 96: 1698–1705
Mayer U, Wagenaar E, Gerlach JH et al . Full blockade of intestinal P-glycoprotein and extensive inhibition of blood–brain barrier P-glycoprotein by oral treatment of mice with PSC833 J Clin Invest 1997 100: 2430–2436
Sikic BI, Fisher GA, Gerlach JH et al . Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein Cancer Chemother Pharmacol 1997 40: S13–19
Van Asperen J, Van Tellingen O, Beijnen JH . The pharmacological role of P-glycoprotein in the intestinal epithelium Pharmacol Res 1998 37: 429–435
van Asperen J, van Tellingen O, Schinkel AH, Beijnen JH . Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein J Pharmacol Exp Ther 1999 289: 329–333
Schinkel AH, Wagenaar E, Mol CA, van Deemter L . P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J Clin Invest 1996 97: 2517–2524
Greenberger LM, Lisanti CJ, Silva JT, Hoirwitz SB . Domain mapping of the photoaffinity drug-binding sites in p-glycoprotein encoded by mouse mdr1b J Biol Chem 1991 266: 20744–20751
Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV . Photoaffinity labeling of human P-glycoprotein: effect of modulator interaction and ATP hydrolysis on substrate binding Meth Enzymol 1998 292: 318–328
Loo TW, Clarke DM . The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface J Biol Chem 1999 274: 24759–24765
Muller M, Bakos E, Gerlach JH et al . Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein J Biol Chem 1996 271: 1877–1883
Urbatsch IL, Sankaran B, Bhagat S, Senior AE . Both P-glycoprotein nucleotide-binding sites are catalytically active J Biol Chem 1995 270: 26956–26961
Ambudkar SV, Dey S, Gerlach JH et al . Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 1999 39: 361–398
Bruggemann EP, Germann UA, Gottesman MM, Pastan I . Two different regions of P-glycoprotein {corrected} are photoaffinity-labeled by azidopine {published erratum appears in J Biol Chem 1990 Mar 5;265(7):4172} J Biol Chem 1989 264: 15483–15488
Bruggemann EP, Chaudhary V, Gottesman MM, Pastan I . Pseudomonas exotoxin fusion proteins are potent immunogens for raising antibodies against P-glycoprotein Biotechniques 1991 10: 202–204, 206, 208–209
Bruggemann EP, Currier SJ, Gottesman MM, Pastan I . Characterization of the azidopine and vinblastine binding site of P-glycoprotein J Biol Chem 1992 267: 21020–21026
Morris DI, Greenberger LM, Gerlach JH et al . Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin Mol Pharmacol 1994 46: 329–337
Mickley LA, Lee JS, Gerlach JH et al . Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors Blood 1998 91: 1749–1756
Hoffmeyer S, Burk O, von Gerlach JH et al . Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 2000 97: 3473–3478
Hori R, Okamura N, Aiba T, Tanigawara Y . Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney J Pharmacol Exp Ther 1993 266: 1620–1625
Kim RB, Fromm MF, Gerlach JH et al . The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors J Clin Invest 1998 101: 289–294
Lee CG, Gottesman MM, Gerlach JH et al . HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter Biochemistry 1998 37: 3594–3601
Lee CG, Gottesman MM . HIV-1 protease inhibitors and the MDR1 multidrug transporter J Clin Invest 1998 101: 287–288
König J, Nies AT, Cui Y, Leier I, Keppler D . Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance Biochim Biophys Acta 1999 1461: 377–394
Keppler D . Export pumps for glutathione S-conjugates Free Radic Biol Med 1999 27: 985–991
Borst P, Evers R, Kool M, Wijnholds J . A family of drug transporters: the multidrug resistance-associated proteins J Natl Cancer Inst 2000 92: 1295–1302
Eichelbaum M, Evert B . Influence of pharmacogenetics on drug disposition and response Clin Exp Pharmacol Physiol 1996 23: 983–985
Nebert DW . Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 1997 60: 265–271
Acknowledgements
This work is supported by a BMBF grant No. 01GG9846 from the German Ministry for Education, Science, Research and Technology.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brinkmann, U., Eichelbaum, M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J 1, 59–64 (2001). https://doi.org/10.1038/sj.tpj.6500001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500001
Keywords
This article is cited by
-
The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial
Scientific Reports (2020)
-
Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters
The Pharmacogenomics Journal (2017)
-
Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis
European Journal of Clinical Pharmacology (2015)
-
Prioritization of SNPs for Genome-Wide Association Studies Using an Interaction Model of Genetic Variation, Gene Expression, and Trait Variation
Molecules and Cells (2012)
-
Association between two polymorphisms of ABCB1 and breast cancer risk in the current studies: a meta-analysis
Breast Cancer Research and Treatment (2011)